Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Septerna discontinues SEP-786 Phase 1 clinical trial in hypoparathyroidism
Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy ...
Muscular Dystrophy News5d
Phase 1 trial of SAT-3247 finishes enrolling healthy volunteers
Enrollment of healthy volunteers for a Phase 1 trial testing Duchenne muscular dystrophy (DMD) treatment candidate SAT-3247 ...
Multiple Sclerosis News Today1d
TG Therapeutics advancing CAR T-cell therapy toward Phase 1 trial
TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...